Gallego Presses Pfizer on Secret Trump Drug Pricing Deal

WASHINGTON - Today, Senator Ruben Gallego (D-AZ) called on Pfizer to provide answers about its newly announced agreement with the Trump administration to implement "Most Favored Nation" (MFN) pricing in Medicaid and launch a new drug purchasing platform, TrumpRx.gov.

READ MORE: Gallego demands transparency in Trump's deal with Pfizer (The Hill)

"To date, few details about this deal have been made public. While the White House touted the agreement as a win for patients, neither the Administration nor Pfizer has disclosed which drugs are covered, what prices have been agreed to, or how patients will benefit," Gallego wrote in a letter to Pfizer CEO Dr. Albert Bourla. "The lack of transparency surrounding this arrangement raises serious concern."

Instead of giving families clarity, Gallego noted, TrumpRx requires patients to bypass their insurance and pay cash for drugs that may be more expensive than their copays.

"In addition to the MFN arrangement, I request clarification on Pfizer's participation in the TrumpRx platform. As currently described, this model would require patients to bypass their insurance and pay cash for medications - often at high out-of-pocket costs," the Senator continued. "Given that many insured patients already have lower copays or coinsurance than the proposed TrumpRx discounts, it is unclear how this platform would provide meaningful relief. In fact, it may increase costs for patients."

Gallego pressed Pfizer to clarify:

• Which countries and pricing metrics will be used in the MFN formula, and whether the pricing will be based on list prices, net prices after rebates and discounts, or some other metric
• Whether Pfizer will disclose how the final MFN price is calculated, including whether discounts, rebates, or pricing agreements are incorporated
• How frequently MFN comparator pricing will be updated as international pricing data changes
• What the full scope of drugs subject to MFN pricing in Medicaid will be

Read the full letter HERE.

10/3/25